IDiyas

For the Inventor, By the Inventor

Pacifica, CA, United States of America

Jennifer Kozak

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2021)
  • Pacifica, CA (US) (2017 - 2023)

Company Filing History:

goldMedal17 out of 262 
 
Theravance Biopharma R&d Ip, LLC
 patents

Years Active: 2017-2025

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor (2025-07-15),
2. 12172994 - Pyrimidine compound as JAK kinase inhibitor (2024-12-24),
3. 11814377 - Pyrimidine compound as JAK kinase inhibitor (2023-11-14),
4. 11780852 - Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2023-10-10),
5. 11730720 - ALK5 inhibitors (2023-08-22),
6. 11673879 - Substituted pyrimidines and methods of use (2023-06-13),
7. 11590116 - Substituted pyridines and methods of use (2023-02-28),
8. 11420965 - Pyrimidine compound as JAK kinase inhibitor (2022-08-23),
9. 11110095 - Pyrimidine compounds as JAK kinase inhibitors (2021-09-07),
10. 10988470 - Pyrimidine compound as JAK kinase inhibitor (2021-04-27),
11. 10952996 - ALK5 inhibitors (2021-03-23),
12. 10947254 - Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2021-03-16),
13. 10774080 - Pyrimidine compound as JAK kinase inhibitor (2020-09-15),
14. 10562894 - Pyrimidine compound as JAK kinase inhibitor (2020-02-18),
15. 10308646 - Pyrimidine compound as JAK kinase inhibitor (2019-06-04),

Title: Jennifer Kozak: A Pioneer in JAK Kinase Inhibition

Introduction: Jennifer Kozak, an innovative inventor based in Pacifica, California, has made significant contributions to the field of pharmaceuticals with a focus on JAK kinase inhibitors. With a remarkable portfolio of 16 patents, her work demonstrates a commitment to advancing therapeutic solutions for various diseases.

Latest Patents: One of Jennifer's latest inventions is a pyrimidine compound that acts as a JAK kinase inhibitor. This invention provides a compound of a specific formula, along with pharmaceutically-acceptable salts that inhibit JAK kinases. Additionally, her invention includes pharmaceutical compositions comprising this compound, details on a crystalline form, methods for treating inflammatory skin diseases, and other related diseases. These patents reflect her deep understanding of medicinal chemistry and its applications in treating complex health issues.

Career Highlights: Jennifer currently works at Theravance Biopharma R&D IP, LLC, where she contributes her expertise in drug development and innovation. Her extensive background and experience in the pharmaceutical industry have allowed her to become a recognized leader in her field.

Collaborations: Throughout her career, Jennifer has collaborated with talented colleagues such as Ryan Hudson and Gary E. L. Brandt. These partnerships have fostered an environment of creativity and innovation, leading to the successful development of several patented compounds.

Conclusion: Jennifer Kozak's dedication to her field and her impressive array of patents highlight her role as a key inventor in pharmaceutical research. Her work in developing JAK kinase inhibitors is paving the way for new treatments, demonstrating her commitment to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…